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ABSTRACT
Integrase strand transfer inhibitor (INSTI)–based regimens dominate
initial human immunodeficiency virus treatment. Most INSTIs are
metabolized predominantly via UDP-glucuronosyltransferases (UGTs).
For drugs predominantly metabolized by UGTs, including INSTIs,
in vitro data recovered from human liver microsomes (HLMs) alone
often underpredict human oral clearance. While several factors may
contribute, extrahepatic glucuronidation may contribute to this
underprediction. Thus, we comprehensively characterized the ki-
netics for the glucuronidation of INSTIs (cabotegravir, dolutegravir,
and raltegravir) using pooled human microsomal preparations from
liver (HLMs), intestine (HIMs), and kidney (HKMs) tissues; human
embryonickidney293cellsexpressing individualUGTs;andrecombinant
UGTs. In vitro glucuronidation of cabotegravir (HLMsHKMs>>>HIMs),
dolutegravir (HLMs>HIMs>>HKMs), and raltegravir (HLMs>HKMs>>
HIMs) occurred in hepatic and extrahepatic tissues. The kinetic data
from expression systems suggested the major enzymes in each
tissue: hepatic UGT1A9 > UGT1A1 (dolutegravir and raltegravir) and
UGT1A1 (cabotegravir), intestinal UGT1A3 > UGT1A8 > UGT1A1
(dolutegravir) and UGT1A8 > UGT1A1 (raltegravir), and renal UGT1A9
(dolutegravir and raltegravir). Enzymes catalyzing cabotegravir glu-
curonidation in the kidney and intestine could not be identified
unequivocally. Using data from dolutegravir glucuronidation as a
prototype, a “bottom-up” physiologically based pharmacokinetic
model was developed in a stepwise approach and predicted
dolutegravir oral clearance within 4.5-fold (hepatic data only),
2-fold (hepatic and intestinal data), and 32% (hepatic, intestinal,
and renal data). These results suggest clinically meaningful
glucuronidation of dolutegravir in tissues other than the liver.
Incorporation of additional novel mechanistic and physiologic
underpinnings of dolutegravir metabolism along with in silico
approaches appears to be a powerful tool to accurately predict
the clearance of dolutegravir from in vitro data.
Introduction
The human immunodeficiency virus (HIV) type 1 infection and the
acquired immune deficiency syndrome (AIDS) are a global major public
health problem. The prevalence of new HIV-1 infections and AIDS-
related morbidity and mortality has considerably decreased over the past
35 years due in part to the continued development of new, highly
effective HIV drugs that work by different mechanisms and the
introduction of novel formulations and drug combinations (Flexner,
2019). HIV-1 infection has now evolved into a manageable disease that
requires lifelong drug therapy. Thus, improving tolerability, efficacy,
and cost-effectiveness of these regimens in the context of a chronic care
model has become an important consideration. However, over 35million
people still live with HIV/AIDS globally (over 1 million in the United
States), and over 900,000 people died of HIV-related illnesses in
2017 alone (https://www.cdc.gov/hiv/statistics/overview/index.html;
https://www.who.int/gho/hiv/en/).
Due to their demonstrated clinical efficacy and excellent safety,
integrase strand transfer inhibitors (INSTIs) in combination with two
nucleoside/nucleotide reverse transcriptases currently dominate HIV
therapy for both antiretroviral-naïve and -experienced patients (DHHS
Panel on Antiretroviral Guidelines for Adults and Adolescents, 2018).
Four INSTIs (bictegravir, dolutegravir, raltegravir, and elvitegravir)
have been Food and Drug Administration approved and are recommended
as preferred initial regimens for most treatment-naïve HIV patients (DHHS
Panel on Antiretroviral Guidelines for Adults and Adolescents, 2018;
Flexner, 2019). Cabotegravir is being developed as both an oral and long-
acting injectable formulation (phase III drug development) for both the
treatment and prevention of HIV infection (Flexner, 2019). Glucur-
onidation via uridine diphosphate-glucuronosyltransferase (UGT)
enzymes (e.g., hepatic UGT1A1) is the main metabolic pathway of
dolutegravir, raltegravir, and cabotegravir (Fig. 1) (Kassahun et al., 2007;
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Castellino et al., 2013; Bowers et al., 2016). Elvitegravir undergoes
oxidation by CYP3A (Mathias et al., 2009), and both oxidation
(CYP3A) and glucuronidation are involved in the metabolism of
bictegravir (https://www.accessdata.fda.gov/drugsatfda_docs/nda/
2018/210251Orig1s000TOC.cfm).
UGTs are typically low-affinity, high-capacity enzyme systems that
have minimal consequences on drug exposure from drug perpetrators
(Williams et al., 2004; Gufford et al., 2015). Those INSTIs and other
drugs mainly cleared by UGTs are thought to be less susceptible to drug-
drug interactions than those observed with substrates of cytochrome
P450s (Williams et al., 2004; Adams et al., 2012; Trezza et al., 2015;
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents,
2018). As a result, UGT-mediated metabolism is an attractive property
for new molecular entities undergoing development due to the
confidence in stable metabolic elimination of the compound (Argikar
et al., 2016). However, accurate in vitro to in vivo extrapolation (IVIVE)
of clinical pharmacokinetics for drugs metabolized via UGT remains
elusive (Argikar et al., 2016). Early-phase development of the INSTIs
found that in vitro and preclinical data reported underprediction of
apparent oral clearance (Laufer et al., 2009). This tendency was
observed across several UGT substrates from other therapeutic classes
(Boase and Miners, 2002; Soars et al., 2002; Laufer et al., 2009). This
underprediction may be due to inadequate applications of the mecha-
nistic and physiologic characteristics of the glucuronidation pathway
and an inadequate understanding of the contribution of UGTs other than
hepatic UGT1A1 (Izukawa et al., 2009; Court et al., 2012; Achour et al.,
2017). Multiple UGTs, including UGT1A1, are expressed in multiple
tissues at varying drug-metabolizing capacities, such as the liver, kidney,
and intestine (Court et al., 2012; Gill et al., 2013;Margaillan et al., 2015;
Drodzik et al., 2018). The possibility that UGTs in extrahepatic tissues
may catalyze the metabolism of INSTIs has not been previously
investigated. Further, the contribution of extrahepatic glucuronidation
Fig. 1. Chemical structures of cabotegravir, dolutegravir, and raltegravir and their respective O-glucuronides (cabotegravir glucuronide, dolutegravir glucuronide, and
raltegravir glucuronide). Red is the site of ether O-glucuronidation.
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to overall systemic clearance of INSTIs remains unknown. The impact
of factors (e.g., drug-drug interactions, organ function, and genetic
variations) influence the exposure via modulation of extrahepatic UGTs
remains elusive. Developing an accurate prediction framework of
in vivo clearance from in vitro data of INSTIs and other UGT substrates
accounting for extrahepatic metabolism is an important step to un-
derstand mechanisms influencing systemic exposure and effect of
INSTIs.
The primary objective of this work was to apply an integrative
approach that incorporated extrahepatic glucuronidation with our current
understanding of hepatic INSTI glucuronidation to improve understand-
ing of clearance mechanisms and predictions of in vivo pharmacokinetics
from in vitro data of INSTIs. Thus, in vitro enzyme kinetic parameters
were recovered to quantitatively describe the major tissue-, isoform-, and
pathway-specific UGT-mediated metabolism of cabotegravir, dolute-
gravir, and raltegravir. Using dolutegravir as an example, the in vitro
hepatic and extrahepatic glucuronidation parameters were then in-
corporated into a physiologically based pharmacokinetic (PBPK) model
to predict clinical pharmacokinetics.
Materials and Methods
Materials and Chemicals. Pooled human liver microsomes (HLMs) from
50 donors with mixed sex [average age: 47 years old (range: 5–83)], pooled
human kidney microsomes (HKMs) from eight donors with mixed sex [average
age: 54 years old (range: 42–70)], and pooled human intestinal microsomes
(HIMs) from 15 donors withmixed sex [average age: 54 years old (range: 26–69)]
were purchased fromXenotech, LLC (Lenexa, KS). UGT-expressing baculovirus-
insect cell systems (Supersomes) were purchased from Corning Incorporated
(Woburn, MA). Human embryonic kidney 293 (HEK293) cells overexpressing
individual UGT1A enzymes were harvested, and microsomes were prepared as
described previously (Sun et al., 2013). Cabotegravir and dolutegravir were
purchased from MedChemExpress, LLC (Monmouth Junction, NJ). Raltegravir
was obtained from the National Institutes of Health AIDS Reagent Program
(Germantown, MD). Cabotegravir glucuronide, dolutegravir glucuronide, and
raltegravir glucuronide were purchased from Toronto Research Chemicals Inc.
(North York, Canada) and were 95% pure as determined by the supplier via
thin-layer chromatography with nuclear magnetic resonance spectroscopy and
mass spectrometry structural confirmation. Alamethicin, magnesium chloride,
8-14-dihydroxy efavirenz, nevirapine, saccharolactone, Tris-HCl, Tris base, and
UDP-glucuronic acid (UDPGA) were purchased from Sigma-Aldrich (St. Louis,
MO). Dimethylsulfoxide, acetonitrile, methanol, ethanol, and formic acid (all
liquid chromatography–mass spectrometry grade) were purchased from Fisher
Scientific (Hampton, NH). Dialysis membranes (12–14 kDa molecular mass
cutoff) were purchased from Fisher Scientific (Hampton, NH). The 96-well
microequilibrium HTD 96b dialysis device was obtained from HTDialysis, LLC
(Gales Ferry, CT).
Liquid Chromatography–Tandem Mass Spectrometry Method Develop-
ment. A new liquid chromatography–tandem mass spectrometry (LC-MS/MS)
method was developed for quantification of cabotegravir, dolutegravir, raltegra-
vir, and their respective glucuronide metabolites. Chromatographic separation
was accomplished using a Phenomenex Luna C18, 5-mM, 4.6 150-mm column
(Torrance, CA) heated to 30C with a binary gradient flow of 0.8 ml/min. The
gradient elution beganwith 40:60 acetonitrile:water (both with 0.1% formic acid),
increased to 90:10 at 5 minutes, and held for 0.5 minutes before returning to initial
conditions for the remaining 2 minutes. Chromatographic separation was
achieved within 7.5 minutes using a single LC method for all compounds
(Supplemental Fig. 1). Samples were analyzed (3-ml injection volume) using the
QTRAP 6500+ LC-MS/MS system (AB Sciex, Framingham, MA) with
turboelectrospray source operated in both positive (confirmation) and negative
(quantification) modes. The negative mode was used to improve glucuronide
metabolite sensitivity and selectivity with confirmatory transitions in positive ion
mode. 8-14-Dihydroxy efavirenz and nevirapine were used as internal standards
for the negative and positive mode, respectively. Compound-specific instrument
parameters were optimized for each analyte (Supplemental Table 1). The incubation-
generated INSTI glucuronides were directly quantified using commercially available
INSTI glucuronide authentic standards with a dynamic assay range of 0–2000 nM.
The instrument response was linear with respect to increasing analyte concentration
over the standard curve range used. The lower limit of quantification was 1 nM
(cabotegravir glucuronide) or 2 nM (dolutegravir and raltegravir glucuronides). Data
were acquired using Analyst software (version 1.6.3; AB Sciex) and quantified via
MultiQuant software (version 3.0.2; AB Sciex). Assay accuracywas evaluated using
MultiQuant software; standard and quality control samples were deemed acceptable
if within 20% of the nominal value except for the lower limit of quantification, which
was assessed with a 30% threshold.
Glucuronidation Kinetics in HLMs, HIMs, and HKMs. Incubation
conditions were optimized for each substrate and enzyme source to ensure
linearity of metabolite formation with respect to time and protein concentration
and to prevent greater than 20% substrate depletion (Supplemental Table 2). To
determine the kinetics for the formation of the glucuronides, cabotegravir,
dolutegravir, and raltegravir (concentrations spanning 0–2000 mM) were in-
cubated in duplicate with each individual tissue microsomal preparation (HLM,
HIM, and HKM protein concentrations shown in Supplemental Table 2) in Tris-
HCl buffer (pH 7.4, 100 mM) containing MgCl2 (5 mM) and bovine serum
albumin (BSA) (0.05%) with a total incubation volume of 150 ml. HLMs, HIMs,
and HKMs were treated with alamethicin (50 mg/mg protein) on ice for
15 minutes. Saccharolactone (100 mM) was added to all HIM preparations.
Mixtures were equilibrated at 37C for 5minutes, and reaction was initiated by the
addition of 15 ml of UDPGA (2 mM final concentration) and incubated for
60 (cabotegravir), 30 (dolutegravir), and 20 (raltegravir) minutes. Reactions were
terminated by removing 100 ml from the incubation and diluting into 300 ml of
ice-cold acetonitrile (0.1% formic acid) containing internal standards nevirapine
(0.2 mM) and 8,14-dihydroxy efavirenz (0.2 mM). Samples were vortex-mixed
and centrifuged at 3000g for 20 minutes at 4C. Supernatant (200 ml) was
transferred to clean 96-well plates for analysis via LC-MS/MS.
Determination of Nonspecific Protein Binding in HLMs, HIMs, and
HKMs. The equilibrium dialysis method described by Gill et al. (2012) was used
to determine the fraction unbound in the incubation, fu,inc, for all three drugs
(cabotegravir, dolutegravir, raltegravir) in pooled HLMs, HIMs, andHKMs in the
presence and absence of BSA. Each INSTI drug (10 mM) in buffer was added to
the donor side of the membrane along with the relevant concentration of
microsomal protein (Supplemental Table 2) with or without BSA (0.05%). Tris-
HCl buffer (pH 7.4, 100 mM) containing MgCl2 (5 mM) and saccharolactone
(100 mM; for HIMs only) was added to the acceptor side of the membrane.
Experiments were performed in duplicate. The plate was left to equilibrate for
6 hours on a plate shaker (250 rpm) at 37C. Aliquots (50 ml) were transferred
from both the acceptor and donor sides of the membrane to 200 ml containing the
internal standard nevirapine (0.2 mM) and methanol (0.1% formic acid). Samples
were vortex-mixed and centrifuged at 3000 rpm for 20 minutes at 4C.
Supernatant (100 ml) was transferred to clean 96-well plates for analysis via
LC-MS/MS as described earlier. Fraction unbound was calculated as follows:
fu;inc¼ ½peak area in acceptor side ðþBSAÞ=½peak area internal standard ðþBSAÞ½peak area in donor side ð2BSAÞ=½peak area internal standard ð2BSAÞ
Reaction Phenotyping Using a Recombinant UGT Enzyme Panel.
Cabotegravir, dolutegravir, or raltegravir (50 mM) was incubated in duplicate
with each individual recombinant UGT (rUGT) enzyme (0.2 mg/ml rUGT 1A1,
1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, 2B17) or vehicle/vector
control as described earlier, except for the absence of alamethicin and
saccharolactone. Reactions were initiated by the addition of 15 ml of UDPGA
(2mM final concentration) and terminated at 60 minutes by transferring 100ml of
each incubation into 300 ml of ice-cold acetonitrile (0.1% formic acid) containing
internal standard and analyzed via LC-MS/MS as described earlier.
Isoform-Specific Glucuronidation Kinetics. Ranging concentrations of
cabotegravir, dolutegravir, or raltegravir (0–2000mM)were incubated in duplicate
with each UGT enzyme source—rUGT1A1, rUGT1A3, rUGT1A7, rUGT1A8,
rUGT1A9, HEKUGT1A1, HEKUGT1A3 (raltegravir only), HEKUGT1A7,
HEKUGT1A8, andHEKUGT1A9—using isoform-specific optimized conditions
for protein concentration and incubation time (Supplemental Table 2). Incubation
vehicle/vector and reaction initiation mirrored that described for the microsomal
preparations except for the absence of alamethicin in rUGT preparations. The
rUGT and HEKUGT incubations did not use saccharolactone. All rUGT
incubations were completed using a single manufacturer lot.
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Physiologically Based Pharmacokinetic Model Development. Dolutegravir
was selected as a prototype for further evaluation of the in vivo contributions of
extrahepatic tissues in INSTI metabolism via PBPK modeling using Certara
SimCYP (version 16.0; Certara, Inc., Princeton, NJ). Dolutegravir modeling was
selected in this manuscript for a number of reasons: 1) it is the most commonly
prescribed clinically, 2) it has sufficient clinical data readily available to confirm
model predictions, and 3) published PBPK models are lacking. The PBPKmodel
was parameterized initially using literature values to describe dolutegravir
physicochemical properties and oxidative metabolism (Supplemental Table 3)
(Castellino et al., 2013; Reese et al., 2013). The advanced dissolution, absorption,
and metabolism (ADAM) model was selected for incorporation of intestinal
glucuronidation and dynamic multicompartmental transit time effects. Standard
SimCYPmodel parameters of potential enterohepatic circulation (100%) from the
compound eliminated from biliary excretion were incorporated. Glucuronidation
kinetics were described in a stepwise fashion via incorporation of in vitro enzyme
kinetic parameters describing hepatic only; hepatic plus renal; and finally, the
combination of hepatic, renal, and intestinal UGT-mediated metabolism. Simula-
tions were conducted using the SimCYP “healthy volunteers”multiple populations
[10 trials with 10 subjects (20–50 years old) in each trial] administered a single
50-mg oral dolutegravir dose under fasted conditions. Published dolute-
gravir clinical pharmacokinetic data with a matching dosing regimen (single
fasted 50-mg oral dose in healthy volunteers) (https://www.accessdata.fda.gov/
drugsatfda_docs/nda/2013/204790Orig1s000TOC.cfm; Song et al., 2015) were
used in the evaluation of PBPK model predictions and recovered using GetData
Graph Digitizer (version 2.26.0.20; GetData Pty Ltd., Kogarah, Australia).
Sensitivity analyses were conducted to quantitatively assess the impact of
extrahepatic glucuronidation parameter (HIM and HKM Clint values) uncertainty
on the pharmacokinetic outcomes of interest [Cmax, area under the curve (AUC),
and ClPO] (Supplemental Fig. 2).
Data Analyses. Apparent kinetic constants for glucuronidation of the test
substrates were obtained via nonlinear regression by fitting Michaelis-Menten,
substrate inhibition, two-site, or Hill equations to substrate concentration ([S])
versus apparent metabolite formation velocity data using Phoenix WinNonlin
(version 7.0; Certara).
The Michaelis-Menten equation is as follows:
v ¼ Vmax*½S
Km þ ½S
where v is the initial rate of reaction, Vmax is the maximum velocity, Km is the
Michaelis-Menten constant (substrate concentration at 0.5 Vmax), and [S] is the
substrate concentration.




where S50 is the substrate concentration resulting in 50% of Vmax (analogous to
Km in the previous equation), and n is the Hill coefficient.
The two-site is as follows:
v ¼ Vmax1*½S
Km1 þ ½S þ
Vmax2*½S
Km2 þ ½S
where Vmax1 and Vmax2 are the maximum velocities, and Km1 and Km2 are the
Michaelis-Menten constants for the two sites of the enzyme.






where Ki is the inhibition constant.
Km and S50 were corrected for nonspecific binding [Km*fu;inc (Km,u and S50,u)].
In vitro Clint,u is calculated as (Vmax/Km,u) and Clmax,u is calculated as [Vmax 
(h2 1)/Km,u + h (h2 1)
1/h] (Houston andKenworthy, 2000), where in vitro Clint,u
is the unbound intrinsic clearance per microsomal protein and is calculated for
substrates described by the simple Michaelis-Menten or Hill equation, re-
spectively. Best-fit models were selected by visual inspection of the predicted
versus observed data, precision of parameter estimates generated from the
nonlinear regression, and Akaike information criteria. Unless noted, data are
presented as the mean of duplicate incubations, with error bars showing data
variability for N = 2.
Scaling from In Vitro Clint to Organ Clint. The in vitro Clint,u was used to
estimate whole organ Clint as follows: in vitro Clint,u * scaling factor (MPPGL,
MPPGK, or MPPI) * organ weight (liver or kidney), where MPPGL is the
microsomal protein per gram of liver, MPPGK is themicrosomal protein per gram
of kidney, and MPPI is the microsomal protein per total intestine. The following
scaling factors were used:MPPGL of 37.69mgmics/g of liver tissue (Wood et al.,
2017) (total liver weight = 1800 g) (Davies and Morris, 1993); MPPGK of
12.8 mg mics/g of renal tissue (Al-Jahdari et al., 2006) (total kidney weight =
310 g) (Davies and Morris, 1993); and MPPI of 2935.17 mg mics/total intestine
(Paine et al., 1997). The microsomal scaling factors are imbedded in the SimCYP
software.
Results
INSTI Glucuronidation is Tissue-Dependent. Glucuronidation
kinetic parameters were recovered with varying concentrations (0–
2000 mM) of cabotegravir, dolutegravir, and raltegravir in pooled
HLMs, HIMs, and HKMs to quantitatively assess tissue-specific INSTI
glucuronidation (Fig. 2; Table 1). To correct the Km values derived for
nonspecific protein binding in incubations (fu,inc), equilibrium dialysis
experiments were performed in pooled HLMs, HIMs, and HKMs.
Incubations tested in the absence of albumin found fu,inc was$0.85 for
cabotegravir, dolutegravir, and raltegravir. Nonspecific protein binding
was observed in the presence of BSA for dolutegravir and cabotegravir,
whereas the fraction unbound for raltegravir was unaffected by either
Fig. 2. Kinetics for the formation of glucuronides from cabotegravir (A),
dolutegravir (B), and raltegravir (C) in HLMs, HIMs, and HKMs. The substrate
concentration versus velocity data were fit to the Michaelis-Menten equation.
Shapes (e.g. circles, triangles) represent observed data (OBS) and solid lines are
predicted (PRED).
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BSA or microsomal proteins (fu,inc was$0.90) (Table 1). Pooled HLMs
had the greatest nonspecific protein binding for dolutegravir, and HKMs
for cabotegravir. There were minimal differences in protein binding
between the different organ tissues (HLMs, HIMs, HKMs) for the same
substrate but noticeable changes in binding among the different INSTI
substrates (Table 1). The fraction unbound (fu,inc) was then used to
estimate the unbound Km (Km,u) values (Table 1), and accordingly, the
in vitro Clint,u was calculated (Table 1). In the subsequent portion of
the manuscript, Km is referred to as Km,u, and in vitro intrinsic clearance
Clint is Clint,u.
Cabotegravir and raltegravir appeared to be relatively low-affinity
substrates for UGTs, as represented by high Km values (167–560 mM)
(Table 1), whereas the Km values for dolutegravir were between 32 and
96 mM. Microsomal UGTs had the lowest affinity for cabotegravir in all
three tissues comparedwith dolutegravir and raltegravir, suggesting slower
metabolism via UGT for cabotegravir. Cabotegravir glucuronide was most
efficiently (in vitro Clint) formed in HLMs and HKMs compared with
HIMs. The Km values for cabotegravir glucuronidation were relatively
high, and saturation was not easily achieved in the case of HIMs,
suggesting that this elimination pathway is low-affinity and high-capacity,
a common observation for UGT-mediated elimination routes. Thus, Km
(.6 mM) and Vmax values were unreliable to estimate in vitro Clint.
Overall, the in vitro metabolism of cabotegravir in HIMs was
relatively small, suggestingminimal intestinal contribution to the overall
metabolic clearance. Intestinal UGTs expressed the lowest affinity
(highest Km) and highest capacity (Vmax) for dolutegravir, while HLMs
and HKMs showed relatively lower Km values (Table 1). Based on the
in vitro Clint, dolutegravir glucuronidation was most efficient in HLMs
(1.5- and 3-fold higher compared with HIMs and HKMs, respectively).
The microsomal preparations suggested raltegravir glucuronidation was
more similar to cabotegravir in terms of tissue involvement. Raltegravir
was glucuronidated predominantly in HLMs and HKMs with lesser
HIM contributions. Raltegravir glucuronidation was higher in hepatic
tissue, reflected by the 4.8-fold greater in vitro Clint compared with
intestinal tissue, and was 2-fold greater compared with renal tissues.
Renal tissue expressed the lowest affinity (Km) but the highest UGT
capacity (Vmax) for raltegravir.
The in vitro Clint was used to estimate in vivo organClint. In contrast to
the in vitro data showing clear contributions of extrahepatic glucur-
onidation, the in vivo Clint data predicted from the in vitro kinetic
parameters indicate a predominant role of hepatic metabolism of these
drugs (Table 1).
INSTI Glucuronidation in Recombinant UGTs. Microsomal
enzyme kinetic data revealed the prominent role of extrahepatic INSTI
glucuronidation and formed the basis for further evaluation of isoform-
specific INSTI glucuronidation. Reaction phenotyping was conducted
using recombinant UGT–expressing baculovirus-insect cell systems to
qualitatively identify specific UGT enzymes responsible for formation
of the respective INSTI glucuronides (Fig. 3). The reaction phenotyping
showed that rUGT1A9 and rUGT1A1 catalyzed glucuronidation of
cabotegravir, dolutegravir, and raltegravir at the highest rate. Other
TABLE 1
Glucuronidation kinetic parameters from pooled human microsomal preparations
Values represent the parameter estimate (S.E.) by fitting substrate concentration to the simple Michaelis-Menten equation (v =
Vmax *[S]/Km + [S]) to metabolite formation velocity using Phoenix WinNonlin (version 7.0). Clint calculated as the ratio of Vmax to Km.
Enzyme Source fu,inc Km,u Vmax Clint,u Clint,organ
mM pmol/min/mg protein ml/min/mg mics l/h per organ
Cabotegravir
HLMs 0.52 350 (41) 705 (35) 2.0 8.1
HIMs 0.69 NDa 1031 (323) NDa NDa
HKMs 0.50 560 (57) 1088 (56) 1.9 0.45
Dolutegravir
HLMs 0.23 32 (2) 601 (13) 18 76
HIMs 0.37 96 (7) 1170 (33) 12 2.1
HKMs 0.29 47 (8) 291 (16) 6.2 1.1
Raltegravir
HLMs 1 183 (23) 1737 (63) 9.5 38.7
HIMs 1 167 (23) 326 (13) 2.0 0.3
HKMs 0.97 493 (59) 2332 (111) 4.7 0.5
aThe substrate concentration versus velocity did not saturate, and the estimated Km (.6 mM) and Vmax values were unreliable. Thus, the
values are not presented, and Clint,u and Clint,organ were not determined (ND).
Micr, microsomal protein.
Fig. 3. Formation rates of glucuronides from 50 mM cabotegravir (A), dolutegravir
(B), and raltegravir (C) in a panel of rUGT isoforms (0.2 mg/ml protein). Control,
vector control.
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isoforms also participated to a small extent in the glucuronidation of
cabotegravir (UGT1A3  UGT1A8), dolutegravir (rUGT1A3 ,,
rUGT1A7 , rUGT1A8 and raltegravir (UGT1A7 , UGT1A8 ,
UGT1A3).
For those isoforms that showed activity (UGT1A1, UGT1A3,
UGT1A7, UGT1A8, and UGT1A9), UGT isoform-specific INSTI
glucuronidation was evaluated in more detail by recovering UGT
enzyme-specific glucuronidation kinetic parameters. Representative sub-
strate concentration versus velocity curves of UGT1A9 and UGT1A1 fit
to Michaelis-Menten or Hill equation are shown in Fig. 4. All three
INSTIs exhibited substrate inhibition kinetics in rUGT1A9 at concen-
trations above 1000mM. Since these concentrations are supratherapeutic,
they were removed to simplify the kinetics to fit the Hill equation. Kinetic
parameters derived for all rUGTs tested are listed in Table 2. Since the
determining factor influencing nonspecific binding was BSA, which was
common for incubations with HLMs and the expression systems, fu,inc
was not estimated for each UGT isoform. Instead, fu,inc derived from
HLMs (see above) was used to account for nonspecific binding to correct
the Km values derived from the expression systems. Accordingly,
adjusted Km (Km,u) and Clint (Clint,u) values were calculated and are
presented for each enzyme (Table 2). Because information on the specific
UGT protein content was not available or provided from the supplier, the
Vmax and Clint should be viewed as nominal values. To obtain insight into
tissue-specific metabolism, the Km values derived from these isoforms
(Table 2) were compared with those obtained from HLMs, HIMs, and
HKMs (Table 1). The Km values for the formation of cabotegravir
glucuronide were much higher in both HIMs and HKMs (Table 1) than
any of those derived from the rUGTs (Table 2). Only the Km value of
rUGT1A8 was close to that in HLMs, but given that UGT1A8 is mainly
expressed in the gut wall, this relationship cannot be fully explained. The
Km value for UGT1A9-mediated cabotegravir glucuronidation was more
than 6-fold lower than in HLMs. Km values derived from rUGTs
(rUGT1A3, 1A8, and 1A9) were close to those for dolutegravir
glucuronidation in HLMs, HIMs, and HKMs. Of note, the Km value for
dolutegravir glucuronidation in rUGT1A1 was much higher (216 mM).
Finally, the Km values for the formation of raltegravir glucuronide in
HLMs and HIMs were close to those derived from rUGT1A1 and
rUGT1A9.
INSTI Glucuronidation Kinetics in HEK Cells Expressing
Individual UGTs. Full UGT isoform-specific INSTI glucuronidation
kinetics were further evaluated using selected HEK cells expressing
individual UGTs (Table 3). A majority of the substrate concentration
versus velocity curves fit the Michaelis-Menten equation, but some fit
to atypical nonhyperbolic enzyme kinetics and were better described
by the sigmoidal equation (Hill equation). The substrate concentration
versus velocity curves for the glucuronidation of the INSTIs by
UGT1A1 and UGT1A9 expressed in the HEK293 cell system are
shown in Fig. 5, with the corresponding kinetic parameters derived for
all HEKUGTs shown in Table 3. As with rUGTs, isoform-specific
protein expression was not available in the subcellular fraction of the
cell lines. Therefore, the presented Vmax and Clint (Table 3) are only
adjusted for total microsomal protein amount and should be viewed as
nominal or relative values and should not be quantitatively compared
between and within cell systems (rUGTs and HEKUGTs). The Km
values for cabotegravir glucuronidation in HEK cells (1A1 = 55 mM
and 1A9 = 163 mM) were higher than those in rUGT1A1 and
rUGT1A9 and were closer to the hepatic Km value (HLMs; 350 mM),
although the values are still notably lower (by approximately 3- to
6-fold) than observed in HLMs. The Km value in intestinal tissue
(millimolar range) for cabotegravir does not concur with any of theKm
values derived from HEK cell UGT isoforms. The reason for this
discrepancy is not clear. The Km values for dolutegravir glucuroni-
dation in HEK cells (1A9 = 46 mM) is close to the Km value obtained
from HLMs (Km = 32 mM) and HKMs (Km = 47 mM); the Km value for
the other hepatic UGT examined in HEKs (1A1 = 96 mM) was 3-fold
higher than in HLMs. Thus, UGT1A9 (and, to a lesser extent, 1A1)
appears to be the main enzyme responsible for dolutegravir glucur-
onidation in the liver and kidney. Dolutegravir glucuronidation in
HIMs (Km = 96 mM) appears to concur with UGT1A1 and UGT1A8
(HEK cell UGT1A1: Km = 96 mM; UGT1A8: Km = 37 mM). The Km
value for raltegravir glucuronidation in UGT1A9 expressed in HEK
cells (Km = 219 mM) was closer to that derived from HLMs (Km =
183 mM). The Km values derived from this enzyme (HEKUGT1A9)
were about half of that observed for raltegravir glucuronidation in
HKMs. This enzyme may in part explain hepatic and renal glucur-
onidation of raltegravir. Considering the lower Km value by UGT1A1
expressed in HEK cells and the Km in rUGT1A1 comparable to that in
HLMs, it seems that both UGT1A1 and UGT1A9 are the active UGTs
in raltegravir glucuronidation. UGT1A8 appears important for
raltegravir glucuronidation in the gut wall (Km value in UGT1A8
expressed in HEK cells = 142 mM vs. 167 mM in HIMs).
Extrahepatic Glucuronidation Contributes to INSTI Metabolism.
Dolutegravir in vitro glucuronidation kinetics from microsomal data
were incorporated into a physiologically based pharmacokinetic model
using SimCYP to predict dolutegravir clinical pharmacokinetics. After
recovering substantial dolutegravir glucuronidation in intestinal tissue,
the ADAM absorption model was selected to input the intestinal
glucuronidation parameters recovered in HIMs. Three PBPK models
were generated to predict dolutegravir clinical pharmacokinetics: 1) in
vitro hepatic glucuronidation clearance only; 2) in vitro hepatic and
intestinal glucuronidation clearance; and 3) in vitro hepatic, intestinal,
and renal glucuronidation clearance (Fig. 6). Empirical scaling factors
were applied to the intestinal and renal glucuronidation intrinsic
clearance (Clint) parameters, as these could not be input via the more
Fig. 4. Kinetics for the formation of glucuronides from cabotegravir (Cabo),
dolutegravir (Dolu), and raltegravir (Ralt) in UGT1A1- and UGT1A9-overexpressing
baculovirus-insect cell system. The substrate concentration versus velocity data were fit
to appropriate enzyme kinetic equations (see Table 2). Circles represent observed data,
and solid lines are predicted.
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mechanistic approach using the UGT isoform- and tissue-specific Km
and Vmax parameters. Sensitivity analyses of these extrahepatic glucur-
onidation parameters revealed that model-predicted Cmax and ClPO were
more sensitive to changes in intestinal Clint, while AUC was more
sensitive to HKM Clint (Supplemental Fig. 1). All three models
incorporated published values describing minor dolutegravir in vitro
oxidative metabolism (CYP3A4) (Reese et al., 2013) and renal
clearance. PBPKmodels underpredicted observed dolutegravir apparent
oral clearance by 4.5-fold, 2-fold, or 32% by incorporating hepatic only;
hepatic and intestinal; or hepatic, intestinal, and renal glucuronidation,
respectively. The model incorporating glucuronidation in all three
tissues predicted observed dolutegravir Cmax and AUC0-24 within 18%
and 38%, respectively (Table 4).
Discussion
This work is the first comprehensive in vitro characterization of
cabotegravir, dolutegravir, and raltegravir glucuronidation in micro-
somes derived from liver and extrahepatic tissues, HEK293 cells
expressing individual UGTs, and recombinant UGTs. We confirmed
involvement of previously reported UGT isoforms and identified
additional enzymes catalyzing the glucuronidation of these INSTIs.
Our study is the first to report that these three INSTIs undergo substantial
TABLE 2
Glucuronidation kinetic parameters from UGT overexpression in baculosomal cell system
Values represent the parameter estimate (S.E.) by fitting substrate concentration to the simple Michaelis-Menten (MM), Hill, or two-site
equation, as described in the Materials and Methods, to metabolite formation velocity using Phoenix WinNonlin (version 7.0).
Enzyme Source Model Km,u or S50,u Vmax n Clint,u or Clmax,u
mM pmol/min/mg total protein ml/min/mg protein
Cabotegravir
rUGT1A1 Two Site 27 (6)a 17 (1)a 0.6
rUGT1A3 MM 46 (7) 3 (0.1) 0.06
rUGT1A7 MM 43 (5) 10 (0.3) 0.2
rUGT1A8 MM 344 (44) 40 (2) 0.1
rUGT1A9 Hill 56 (7) 61.4 (3) 1.26 (0) 1.1
Dolutegravir
rUGT1A1 MM 216 (26) 507 (50) 2.3
rUGT1A3 MM 62 (7) 18 (0.7) 0.3
rUGT1A7 MM 9 (2) 1 (0) 0.1
rUGT1A8 Hill 44 (5) 7 (0) 1.9 (0) 0.2
rUGT1A9 Hill 39 (3) 39 (2) 1.9 (0) 1.0
Raltegravir
rUGT1A1 MM 260 (17) 334 (7) 1.3
rUGT1A3 Hill 41 (2) 30 (1) 1.7 (0) 0.55
rUGT1A7 MM 452 (56) 23 (1) 0.05
rUGT1A8 MM 386 (57) 39 (2) 0.1
rUGT1A9 Hill 193 (12) 459 (14) 1.45 (0) 1.3







. n, Hill coefficient in the Hill equation.
aThe low-affinity enzyme substrate concentration versus velocity did not saturate, and the estimated Km (.2 mM) and Vmax values were
unreliable. Thus, only the high Km is presented and calculated for Clint,u.
TABLE 3
Glucuronidation kinetic parameters from UGT overexpression in HEK cell system
Values represent the parameter estimate (S.E.) by fitting substrate concentration to the simple Michaelis-Menten (MM) or Hill equation,
as described in the Materials and Methods, to metabolite formation velocity using Phoenix WinNonlin (version 7.0).
Enzyme Source Model Km,u or S50,u Vmax n Clint,u or Clmax,u
mM pmol/min/mg total protein ml/min/mg protein
Cabotegravir
HEKUGT1A1 MM 55 (9) 7 (0) 0.1
HEKUGT1A7 MM 23 (6) 9 (0) 0.3
HEKUGT1A8 MM 133 (5) 12 (0) 0.09
HEKUGT1A9 MM 163 (6) 25 (0) 0.2
Dolutegravir
HEKUGT1A1 MM 96 (15) 21 (1) 0.2
HEKUGT1A7 Hill 2 (3) 2 (0) 1.4 (0) 1.1
HEKUGT1A8 Hill 37 (2) 36 (1) 1.4 (0) 1.0
HEKUGT1A9 Hill 46 (3) 107 (4) 1.7 (0) 2.3
Raltegravir
HEKUGT1A1 Hill 52 (7) 17 (1) 1.5 (0) 0.4
HEKUGT1A3 Hill 22 (1) 2 (0) 1.7 (0) 0.05
HEKUGT1A7 MM 79 (8) 6 (0) 0.07
HEKUGT1A8 Hill 142 (15) 6 (0) 1.4 (0) 0.1
HEKUGT1A9 Hill 219 (29) 24 (1.4) 1.5 (0) 0.06







. n, Hill coefficient in the Hill equation.
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extrahepatic glucuronidation. Using dolutegravir in vitro hepatic and
extrahepatic metabolism, we showed that a “bottom-up” PBPK model
incorporating extrahepatic glucuronidation accurately predicted dolute-
gravir clinical pharmacokinetics from in vitro data. These results suggest
the occurrence of clinically meaningful glucuronidation in tissues other
than the liver—specifically, intestine and kidney. Incorporation of
additional novel mechanistic and physiologic underpinnings of dolute-
gravir metabolism along with in silico approaches appear to be powerful
tools to accurately predict the clearance of dolutegravir from in vitro
data.
Our data showed that all INSTIs tested undergo efficient glucuroni-
dation in HLMs. The INSTI hepatic UGT enzyme kinetic parameters
reported in this work were similar to those values published in the
literature (Kassahun et al., 2007; Reese et al., 2013; Trezza et al., 2015).
Underprediction of oral clearance for UGT substrates using IVIVE
approaches is quite common, and several factors may contribute to this
problem (Boase and Miners, 2002; Soars et al., 2002). It is well
established that UGTs are differentially expressed in hepatic and
extrahepatic tissues (Guillemette et al., 2014; Margaillan et al., 2015;
Drodzik et al., 2018). Therefore, it is possible that this tissue-specific
expression contributes to INSTI glucuronidation. Indeed, our data are
the first to demonstrate that these drugs undergo efficient extrahepatic
glucuronidation in microsomes derived from human kidney and in-
testinal tissues. Based on the in vitro Clint displayed in Table 1: 1) HLMs
andHKMs equally contribute toward cabotegravir glucuronidation, with
minor involvement of HIMs; 2) HLMs and then HIMs contributed to
dolutegravir glucuronidation, with minor participation from HKMs; and
3) the metabolism of raltegravir was approximately 2- and 5-fold higher
in HLMs than in HKMs and HIMs, respectively. On the basis of in vivo
Clint, we noted that HLMs alone provide a larger contribution to INSTI
glucuronidation with minor contribution from extrahepatic tissue in
contrast to the data derived in vitro. While understanding the total
activity per organ is desirable, the uncertainty of the absolute UGT
amount in the gut and kidney makes this comparison less accurate. In
addition, the in vitro data only show the ability of the enzyme systems in
those tissues to metabolize the drugs. The in vitro data suggest that the
gut and kidney are clearly capable of metabolizing the drugs. However,
when considering factors such as the overall size of the organ, blood
flow, drug uptakes, and other physiologic parameters, it is clear that the
liver still plays a major role. There is no doubt that the liver is the main
contributor, but without including the gut and kidney, it is not possible to
predict the pharmacokinetic behavior of these compounds accurately, as
shown in our dolutegravir PBPK model.
We tested the hypothesis that extrahepatic metabolism contributes to
INSTI glucuronidation in vivo. Using dolutegravir glucuronidation data
derived fromHLMs, HIMs, and HKMs, we developed a PBPKmodel to
show that incorporation of extrahepatic glucuronidation substantially
improves the accuracy of PBPKmodel predictions (Fig. 6). Although the
absolute bioavailability of dolutegravir remains unknown, the high gut
and liver involvement in dolutegravir glucuronidation is suggestive of
significant first-pass metabolism, while kidney glucuronidation also
contributes to systemic clearance (Supplemental Fig. 2). This PBPK
model will be tested and validated in the future for IVIVE for other
INSTIs and substrates of UGTs.
The comprehensive characterization of the INSTIs glucuronidation in
recombinant UGTs (Table 2) and in HEK293 cells expressing individual
UGTs (Table 3) provides important insights into isoform-specific
metabolism of these drugs, as summarized in Table 5. We are aware
that additional inhibition analysis could have added valuable informa-
tion in addition to the Km determinations. However, there are no
selective and specific inhibitors of UGT that allow unequivocal
Fig. 5. Kinetics for the formation of glucuronides from cabotegravir (Cabo),
dolutegravir (Dolu), and raltegravir (Ralt) in UGT1A1- and UGT1A9-
overexpressing human embryonic kidney cell lysates. The substrate concentration
versus velocity data were fit to appropriate enzyme kinetic equation (see Table 3).
Circles represent observed data, and solid lines are predicted.
Fig. 6. Application of PBPK model to predict pharmacokinetics of a single 50-mg
oral dose of dolutegravir from in vitro data. Predicted mean concentration versus
time profiles (solid lines) with 95th and 5th percentiles (dashed lines) incorporating
in vitro glucuronidation kinetics in a stepwise approach from HLMs (A); HLMs and
HIMs (B); and HLMs, HIMs, and HKMs (C), overlaid with observed clinical data
(squares) are shown.
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identification of individual isoforms. Our data from expressed UGTs
generally agree well with published literature identifying the enzymes
active in the respective INSTI glucuronidation; however, qualitative
differences are noted. We found that UGT1A9 and UGT1A1 are major
contributors of cabotegravir, dolutegravir, and raltegravir metabolism,
with contribution from other isoforms (UGT1A3, UGT1A7, and
UGT1A8). Poor predictions were observed for cabotegravir metabolism
with regard to the tissue-specific relationship to specific UGT isoforms
due to large differences in Km values. The supraphysiological Km values
in hepatic and extrahepatic tissues along with two-site enzyme kinetics
(Fig. 4) suggest multiple isoforms may be responsible for cabotegravir’s
glucuronidation in the different tissues. For dolutegravir, UGT1A9 Km
values were similar to those found in hepatic and renal tissue. Similarly,
UGT1A1 and UGT1A9 Km values were similar to hepatic and intestinal
tissue with regard to raltegravir glucuronidation. This suggests UGT1A9
may be the major isoform responsible for hepatic glucuronidation of
dolutegravir and raltegravir. Considering that UGT1A9 is predomi-
nantly expressed in the kidney, this enzyme may also be the major
isoform for renal glucuronidation of dolutegravir and raltegravir.
UGT1A9 has been reported as undetectable in gastrointestinal tissue
(Strassburg et al., 2000; Komura and Iwaki, 2011) and, thus, is unlikely
to contribute to the intestinal glucuronidation of raltegravir (and
dolutegravir) despite similar Km values in HIMs and UGT1A9
(Strassburg et al., 2000; Komura and Iwaki, 2011). UGT1A1 appears
to participate in hepatic and intestinal glucuronidation of raltegravir.
Based on the Km values in HEK cell expression system data, UGT1A8,
an enzyme mainly expressed in the intestine (Strassburg et al., 2000;
Komura and Iwaki, 2011), appears to be important in the intestinal
glucuronidation of dolutegravir and raltegravir. It is important to note
that the kinetic data obtained from baculovirus-insect Supersomes
(rUGT) and HEK293 UGT-overexpressed cell lysates should be
interpreted carefully because they were normalized to total protein
instead of specific UGT protein amount (Tables 2 and 3). TheKm values
between cell systems for the same isoform broadly agreewith each other,
with slight differences. It appears that HEK-expressed UGT1A8 and
UGT1A9 correlate better with HIMs and HLMs for dolutegravir and
raltegravir glucuronidation. This additional layer of understanding may
facilitate quantitative assessment of genetic variation and nongenetic
perturbations to UGT metabolism caused by changes in the underlying
system and may allow for better prediction of clinical impact.
The clinical relevance of pharmacogenomic variation contributing to
the observed variability of integrase inhibitor disposition is limited for
UGT1A1 and nearly nonexistent for UGT1A9 and the other UGTs. The
UGT1A1 gene is highly polymorphic, with common genetic variants that
reduce hepatic UGT1A1 activity (*6, *28, *36, and *37 are the most
studied) (Wenning et al., 2009; Adams et al., 2012; Yagura et al., 2015).
Chen et al. (2014) reported that dolutegravir clearance was significantly
reduced and its exposure increased in carriers of low- and reduced-
activity polymorphisms compared with subjects with normal activity.
A similar statement is presented in the Food and Drug Administration–
approved dolutegravir package insert (Food and Drug Administration,
Office of Clinical Pharmacology Review, 2015). A recent study showed
that UGT1A1*6 and *28 alleles individually and in combination are
significantly associated with higher dolutegravir plasma trough concen-
trations and neuropsychiatric events (Yagura et al., 2017). A similar
response was seen with raltegravir (Wenning et al., 2009; Yagura et al.,
2015; Lee et al., 2016; Belkhir et al., 2018). There is still much to learn
about the clinical implications of genetic variability in the UGT system
and the importance in patient response or safety. First, no data are
available regarding pharmacogenetics of cabotegravir, and the impact of
genetic variations in other UGTs on INSTI exposure remains unstudied.
Second, the tissue-specific impact of pharmacogenomic variability in
extrahepatic UGT expression and implications for drug metabolism
remain relatively unexplored.
In summary, significant glucuronidation occurs in various tissues
throughout the body, with the liver, kidney, and intestine being
particularly important for orally administered drugs. The degree of
contribution from each tissue is UGT substrate- and isoform-specific
and must be taken into account to improve in vitro prediction of
in vivo behavior. Incorporation of in vitro hepatic, intestinal, and
renal glucuronidation in a PBPK model achieved predicted dolute-
gravir clearance within 32%, Cmax within 17%, and AUC0-24 within
38% of observed data. Dynamic modeling and simulation ap-
proaches, along with clinical assessment, are needed to produce a
useful tool to predict perturbations to the underlying system and
individualize patient care.
TABLE 4
Dolutegravir clinical pharmacokinetic outcomes recovered from observed data and PBPK model predictions from 1) HLMs only; 2) HLMs and HIMs; and 3) HLMs, HIMs,
and HKMs [geometric mean and coefficient of variation (CV%) incorporating in vitro glucuronidation kinetics data from 1) HLMs only; 2) HLMs and HIMs; and 3) HLMs,
HIMs, and HKMs]




mg/ml mg·h/ml l/h h % % %
Observed 2.2 (43) 43.7 (45) 1.1 (45) 14.4 (19) N/A
HLMs only 5.8 (19) 199.6 (55) 0.3 (50) 21.1 (40) 99.2 0.8 98 99 100
HLMs and HIMs 2.7 (24) 89.4 (55) 0.56 (50) 21.1 (40) 99.2 0.8 46 99 100
HLMs, HIMs, HKMs 2.6 (24) 60.4 (43) 0.8 (44) 15.3 (37) 79.7 20.3 46 99 100
TABLE 5
Summary of the tissue- and isoform-specific UGTs responsible for cabotegravir, dolutegravir, and raltegravir metabolism
based on relations of Km values derived from expression systems
HLMs HIMs HKMs
Cabotegravir UGT1A1a ND ND
Dolutegravir UGT1A9 . UGT1A1a UGT1A3 . UGT1A8 . UGT1A1a UGT1A9
Raltegravir UGT1A9 . UGT1A1 UGT1A8 . UGT1A1 UGT1A9
ND, not determined.
aGreater than 2-fold difference in isoform UGT Km value from that observed for the tissue Km value.
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